Summary
The parmacokinetics of disopyramide (DP) in 10 patients with imminent to moderate cardiac failure has been studied and compared with the results in normal volunteers. The biological half life of rapid distribution (T1/2 α) and of elimination (T1/2 β) were increased (11.1±4.4 min and 9.7±4.2 h, respectively). Total body clearance (Clt) was decreased (0.467±0.215 ml · min−1 · kg−1), and the volume of distribution (Vd) was slightly reduced (0.610±0.1361 · kg−1), probably due to the lower cardiac index. After oral administration, the time to peak serum concentration was increased (139±89 min), and the mean peak serum concentration (2.4±0.8% dose · 1−1) was also higher than reported in normal subjects. Comparison of the areas under the concentration versus time curves after intravenous and oral administration (AUC i. v. and AUC oral) showed that DP was almost completely absorbed, its bioavailability being 97.5±15.0%.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bellet S, Roman FLR, Boza FA (1971) Relation between serum quinidine levels and renal function. Am J Cardiol 27: 368–371
Benowitz NL, Meister W (1976) Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1: 389–405
Bredesen JE (1980) Rapid isothermal determination of disopyramide and its mono-N-dealkylated metabolite in serum using a nitrogen-selective detector. Clin Chem 26: 638–640
Bryson SM, Whiting B, Lawrence JR (1975) Disopyramide serum and pharmacological effect kinetics applied to the assessment of bioavailability. Br J Clin Pharmacol 6: 409–413
Chien YW, Lambert HJ, Karim A (1974) Comparative binding of disopyramide phosphate and quinidine sulphate to human plasma proteins. J Pharmacol Sci 63: 1877–1879
Collste P, Karlsson E (1973) Arrhythmia prophylaxis with procaine amide: Plasma concentrations in relation to dose. Acta Med Scand 194: 405–411
Crouthamel WG (1975) The effect of congestive heart failure on quinidine pharmacokinetics. Am Heart J 90: 335–339
Cunningham JL, Shen DD, Shudo J, Azarnoff DL (1978) The effect of non-linear disposition kinetics on the systemic availability of disopyramide. Br J Clin Pharmacol 5: 343–346
Danilo P Jr, Hordof AJ, Rosen MR (1977) Effects of disopyramide on electrophysiologic properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 201: 701–710
Deano DA, Wu D, Mautner RK, Sherman RH, Ehsani AE, Rosen KM (1977) The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. Chest 71: 597–606
Ditlefsen EML (1957) Quinidine concentration in blood and excretion in urine following parenteral administration as related to congestive heart failure. Acta Med Scand 159: 105–109
Garret ER, Hinderling PH (1975) Pharmacokinetics of disopyramide in healthy human subjects. Clin Pharmacol Ther 17: 234
Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke K, Mac Laughlin DS, Smith TW, Koch-Weser J (1977) Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J Pharmacol Exp Ther 202: 365–378
Hinderling PH, Garrett ER (1976) Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokinet Biopharm 4: 199–230
Hulting J, Rosenhamer G (1976) Antiarrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia. J Int Med Res (Suppl) 1: 90–95
Hulting J, Rosenhamer G (1976) Haemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. Acta Med Scand 199: 41–51
Jones MBS (1976) The use of disopyramide in the treatment of arrhythmias in ambulatory patients. J Int Med Res (Suppl) 1: 86–89
Karim A (1975) The pharmacokinetics of norpace. Angiology (Suppl) 1 (part 2): 85–98
Koch-Weser J (1971) Pharmacokinetics of procainamide in man. Ann NY Acad Sci 179: 370–382
Koch-Weser J (1979) Drug therapy, Disopyramide. N Engl J Med 300: 957–967
Landmark K, Storstein L, Larsen A (1979) Disopyramide plasma levels in cardiac patients on maintenance therapy. Acta Med Scand 206: 385–389
Mizgala HF, Huvelle PR (1976) Acute termination of cardiac arrhythmias with intravenous disopyramide. J Int Med Res (Suppl) 1: 82–85
Noether G (1971) Introduction to statistics. Houghton Mifflin, New York
Price HL, Kovnat PJ, Safer JN, Conner EH, Price M-L (1960) The uptake of thiopental by body tissues and its relation to the duration of narcosis. Clin Pharmacol Ther 1: 16–22
Rangno RE, Warnica W, Ogilvie RI, Kreeft J, Bridger E (1976) Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia. J Int Med Res (Suppl) 1: 54–58
Wagner JG, Northolm JI, Alway CD, Carpenter OS (1965) Blood levels of drugs at the quilibrium state after multiple dosing. Nature 207: 1301–1302
Ward JW, Kinghorn GR (1976) The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens. J Int Med Res (Suppl) 1: 49–53
Whiting R, Miller S (1977) Disopyramide pharmacokinetics: Relationship to bioavailability and renal impairment. In: Ankier SJ, Woodings DF (eds) Proceedings of the Disopyramide (Rhythmodan) Seminar held in the School of Pythagoras, St. Johns College, Cambridge, March 24–25th 1977, p 11–21
Whiting B (1979) Disopyramide pharmacokinetics: Therapeutic implication. In: Boye E, Woodings DF (eds) Proceedings of the Symposium on Arrhythmias held in Moltkes Palae, Copenhagen, September 28th and 29th 1979, pp 80–85
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Landmark, K., Bredesen, J.E., Thaulow, E. et al. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. Eur J Clin Pharmacol 19, 187–192 (1981). https://doi.org/10.1007/BF00561947
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561947